DEPAKOTE 500 mg Cpr gastro-rés Plq/90

▼This medicine is subject to additional monitoring which will allow rapid identification of new safety information. Healthcare professionals should report any suspected adverse reactions. See section Adverse effects for the reporting procedures for adverse reactions.

Gastro-resistant tablet.
Box of 90 tablets, under blister packs.

For one gastro-resistant tablet:

Sodium divalproate: 538,200 mg
Quantity corresponding to valproic acid: 500,000 mg

Excipient with known effect: carmine red (E124).

This medicine contains sodium (see section Warnings and precautions).

Excipients:

In adults

Treatment of manic episodes of bipolar disorder in cases of contraindication or intolerance to lithium.

Continuation of treatment after the manic episode may be considered in patients who responded to sodium divalproate during the acute episode.

Female children and women of childbearing potential

Valproate treatment must be initiated and monitored by a specialist physician experienced in the management of bipolar disorder.

Valproate should not be used in women of childbearing potential unless there is ineffectiveness or intolerance to other treatments. In this case, valproate must be prescribed and dispensed in accordance with the valproate pregnancy prevention programme (see sections Contraindications and Warnings and precautions).

Adolescents and men of childbearing potential

It is recommended that valproate treatment be initiated and monitored by a specialist physician experienced in the management of bipolar disorder (see sections Warnings and precautions and Fertility, pregnancy and breastfeeding).

Method of administration

Oral use.

Dosage

Manic episodes of bipolar disorder:

In adults

The daily dose will be established and individually monitored by the physician.

The recommended initial dose is 750 mg per day. In addition, in clinical trials, an initial dose of 20 mg/kg of sodium divalproate also showed a satisfactory tolerability profile.

The dosage will then be increased as quickly as possible to reach the minimum effective dose. The daily dosage must be adapted to each patient's clinical response in order to establish the individual minimum effective dose.

The average dosage is usually between 1 000 and 2 000 mg of sodium divalproate per day.

Patients receiving doses above 45 mg/kg/day must be closely monitored.

Continuation of treatment following the manic episode of bipolar disorder must be individually adapted using the minimum effective dose.

In elderly patients

Changes in pharmacokinetic parameters have been observed in this population (decreased clearance of free valproate, decreased binding of valproate to proteins). Caution is therefore recommended regarding dose determination. The initial dose must be reduced and the dosage will be established according to the clinical response.

In children and adolescents

The efficacy of DEPAKOTE in children under 18 years of age in the treatment of manic episodes of bipolar disorder has not been established. This medicine is not recommended in children and adolescents. For safety information in children, see section Adverse effects.

In case of renal or hepatic function abnormalities (see sections Contraindications and Warnings and precautions).

Patients with renal impairment

In patients with renal impairment, it may be necessary to reduce the dose, and in patients on haemodialysis, it may be necessary to increase it. Sodium valproate is dialysable (see section Overdose). The dose must be adjusted according to the patient's clinical monitoring (see section Warnings and precautions).

• Pregnant women (see sections Warnings and precautions and Fertility, pregnancy and breastfeeding).
• Women of childbearing potential, unless all the conditions of the pregnancy prevention programme are met (see sections Warnings and precautions and Fertility, pregnancy and breastfeeding).
• History of hypersensitivity to valproate, divalproate, valpromide or to any of the excipients mentioned in section Composition.
• Acute hepatitis.
• Chronic hepatitis.
• Personal or family history of severe hepatitis, in particular drug-induced.
• Hepatic porphyria.
• Patients with known urea cycle disorders (see section Warnings and precautions).
• Patients with a primary systemic carnitine deficiency, not corrected (see section Warnings and precautions "Patients at risk of hypocarnitinaemia").
• Valproate is contraindicated in patients with known mitochondrial disorders caused by mutations in the nuclear gene encoding the mitochondrial enzyme polymerase gamma (POLG), e.g. Alpers-Huttenlocher syndrome, and in children under two years of age suspected of having a POLG-related disorder (see section Warnings and precautions).
• Association with St John's wort (see section Interactions).

Warnings

The molecule "sodium divalproate" is composed of one molecule of sodium valproate and one molecule of valproic acid in a ratio of 1/1.

As this medicine is converted into valproic acid in the body, it should not be combined with other medicines undergoing the same conversion in order to avoid an overdose of valproic acid (for example: valpromide, valproate).

Pregnancy prevention programme

Valproate is a potent teratogen causing a high risk of congenital malformations and neurodevelopmental disorders in children exposed in utero to valproate (see section Fertility, pregnancy and breastfeeding). Valproate must not be used in women of childbearing potential unless there is ineffectiveness or intolerance to other treatments. If no other alternative therapy (drug or non-drug) is possible, comply with the pregnancy prevention programme below.

DEPAKOTE is contraindicated in the following cases: In pregnant women (see sections Contraindications and Fertility, pregnancy and breastfeeding). In women of childbearing potential, unless all the conditions of the pregnancy prevention programme are met (see sections Contraindications and Fertility, pregnancy and breastfeeding).

Conditions of the pregnancy prevention programme

The prescriber must ensure that: individual situations are assessed on a case-by-case basis, involving the patient in the discussion to ensure her commitment, to discuss alternative therapeutic options (drug or non-drug) and to ensure she has understood the risks and the measures necessary to reduce these risks; the risk of pregnancy is assessed in all female patients; the patient has fully understood and is aware of the risks of congenital malformations and neurodevelopmental disorders, including the extent of these risks for children exposed to valproate; in utero in utero; the patient understands the need to carry out a pregnancy test before starting treatment and during treatment, as needed; the patient has been counselled on contraception and is able to comply with the need to use effective contraception (for more details, see the sub-section "Contraception" in this box), without interruption, throughout the entire duration of valproate treatment; the patient understands the need for a specialist physician experienced in the management of bipolar disorders to regularly reassess (at least annually) the treatment; the patient understands the need to consult her doctor as soon as she is considering a pregnancy in order to discuss it in good time and to use alternative therapeutic options before conception, and this before stopping contraception; the patient understands the need to urgently consult her doctor in case of pregnancy; the patient has received the patient information leaflet; the patient has acknowledged that she has understood the risks and necessary precautions associated with the use of valproate (shared information attestation).

These conditions also apply to women who are not sexually active, unless the prescriber considers that there are indisputable reasons indicating that there is no risk of pregnancy.

Pregnancy test

Pregnancy must be ruled out before initiating valproate treatment. Valproate treatment must not be initiated in women of childbearing potential without obtaining a negative pregnancy test (plasma pregnancy test with a sensitivity of at least 25 mIU/mL), confirmed by a healthcare professional, in order to eliminate any possibility of unintentional use of the product during pregnancy. This pregnancy test must be repeated at regular intervals during treatment.

Contraception

Women of childbearing potential receiving valproate must use effective contraception, without interruption and throughout the entire duration of valproate treatment. These patients must receive complete information on pregnancy prevention, as well as contraceptive counselling if they do not use effective contraception. At least one effective contraceptive method (preferably a method whose effectiveness does not depend on the user, such as an intrauterine device or an implant), or two complementary contraceptive methods including a barrier method, must be used. When choosing the contraceptive method, individual situations must be examined on a case-by-case basis, involving the patient in the discussion to ensure her commitment and compliance with the chosen measures. All advice relating to effective contraception must be followed, even in case of amenorrhoea.

Oestrogen-containing medicinal products

Concomitant use with oestrogen-containing medicinal products, including oestrogen-containing hormonal contraceptives, may potentially lead to a decrease in the effectiveness of valproate (see section Interactions). Prescribing physicians should monitor the clinical response (mood control) when initiating or stopping medicinal products containing oestrogens.

Conversely, valproate does not reduce the effectiveness of hormonal contraceptives.

Annual evaluation of treatment by a specialist physician

The specialist physician must reassess the valproate treatment at least annually to verify whether it remains the most appropriate treatment for the patient.

The specialist physician must discuss the shared information attestation at the time of treatment initiation and at each annual review, and must ensure the patient has understood its content. The shared information attestation must be duly completed and signed by the prescriber and the patient (or her legal representative).

Pregnancy planning

In women planning a pregnancy, a specialist physician experienced in the management of bipolar disorder must be consulted, valproate treatment must be stopped and, if necessary, replaced by an alternative therapy (drug or non-drug) before conception and before contraception is discontinued.

In case of pregnancy

Treatment with DEPAKOTE is contraindicated during pregnancy; it must therefore be discontinued immediately if pregnancy is discovered. If a woman taking valproate becomes pregnant, she must be immediately referred to a specialist physician experienced in managing bipolar disorder, in order to stop valproate treatment and consider alternative options. Patients whose pregnancy was exposed to valproate, as well as their partners, must be referred to a specialist or physician experienced in teratology for assessment and advice (see section Fertility, pregnancy and breastfeeding).

The pharmacist must ensure that: the patient card is given with each dispensing of valproate and that patients understand its content; patients are advised to contact a specialist physician immediately if they plan or suspect a pregnancy.

Information materials

In order to help healthcare professionals and patients avoid any foetal exposure to valproate, the marketing authorisation holder provides them with information materials aimed at reinforcing the warnings regarding the teratogenicity (congenital malformations) and foetotoxicity (neurodevelopmental effects) of valproate, and at providing recommendations to women of childbearing potential regarding the use of valproate, as well as details of the pregnancy prevention programme. A patient card and a patient information leaflet must be provided to all patients who use valproate.

A shared information acknowledgement form must be used, duly completed and signed at the time of treatment initiation and at each annual reassessment of valproate treatment by the specialist physician and the patient (or her legal representative).

Use in adolescents and men of reproductive potential

A retrospective observational study suggests an increased risk of neurodevelopmental disorders (NDD) in children whose father was treated with valproate in the 3 months preceding conception compared with those whose father was treated with lamotrigine or levetiracetam. However, other studies do not suggest an increased risk of NDD after paternal exposure to valproate. Consequently, the available evidence is conflicting and the causal role of valproate is uncertain (see section Fertility, pregnancy and breastfeeding).

As a precautionary measure, the prescriber must inform adolescents and men of reproductive potential of this potential risk (see section Fertility, pregnancy and breastfeeding) and discuss with them: the need to use effective contraceptive measures during valproate treatment and for at least three months after its discontinuation, including for their partner, not to donate sperm during valproate treatment and for at least three months after discontinuation of valproate (see section Fertility, pregnancy and breastfeeding).

Valproate treatment in adolescents and men of reproductive age must be regularly reassessed by the prescriber in order to determine whether valproate remains the most appropriate treatment. For male patients planning to father a child, therapeutic alternatives must be considered and discussed with patients. Individual situations must be assessed on a case-by-case basis. It is recommended to seek advice from a physician specialized in the management of bipolar disorder.

Risk minimisation materials are available for healthcare professionals as well as for adolescents and men of reproductive potential.

A shared information acknowledgement form must be used, duly completed and signed at the time of treatment initiation by the specialist physician and at each annual reassessment of valproate treatment by any physician and the patient (or his legal representative).

A patient information brochure must be provided to adolescents and men of reproductive potential using valproate.

Due to the significant interindividual variability in treatment effect, particular caution should be exercised when increasing the dose (see section Dosage and administration).

Any overdose will be monitored clinically (disturbances of consciousness), as total plasma concentrations of circulating valproic acid do not provide information on the free fraction, which is responsible for effects on the central nervous system.

Cases of coma preceded by disturbances of vigilance, which may be associated with hyperammonaemia, have been reported, most often at the start of treatment, in patients receiving polytherapy (in particular, psychotropic drugs).

Therefore, in order to limit this risk, the dose should be increased gradually (see section Dosage and administration) and clinical monitoring should be carried out during the therapeutic adjustment period.

In patients with renal impairment or in the presence of certain medicinal products (see section Interactions), the dose should be reduced.

In elderly patients, the risk of encephalopathy (see Confusional and convulsive states, Undesirable effects) is increased. It is therefore recommended to systematically reduce the initial dose and to increase doses very gradually and with caution according to clinical response, while monitoring for the risk of confusion.

Severe hepatic disorders

Hepatic disorders with a severe course, sometimes fatal, have been reported exceptionally.

Suggestive signs

Early diagnosis remains primarily based on clinical findings. In particular, attention should be paid to 2 types of manifestations that may precede jaundice:

• such as non-specific general signs, generally of sudden onset, such as asthenia, anorexia, malaise, drowsiness, sometimes accompanied by repeated vomiting and abdominal pain, or
• neurological complications, signs of severe hepatopathy.

It is recommended to inform the patient that the onset of such a presentation should immediately prompt a consultation. This consultation will include, in addition to the clinical examination, the immediate performance of a biological test of hepatic function.

Detection

Monitoring of liver function must be carried out before the start of treatment and regularly during the 6 first months of treatment, particularly in patients at risk.

In case of modification of associated treatments known for their hepatic toxicity (increase in dose or new treatment), biological liver monitoring must be set up again (see also section Interactions on the risk of liver damage with salicylate derivatives, other anticonvulsants including cannabidiol).

Among the classic tests, those reflecting protein synthesis, and in particular the PT (prothrombin time), are the most relevant. Confirmation of an abnormally low prothrombin time, especially if accompanied by other biological abnormalities (significant decrease in fibrinogen and coagulation factors, increased bilirubin, elevated transaminases - see subsection " Precautions for use "), should lead to stopping treatment with this medicine (as well as, out of caution and if they are co-prescribed, salicylate derivatives, since they use the same metabolic pathway).

Pancreatitis

Cases of pancreatitis, sometimes fatal in outcome, have been very rarely reported. They may occur regardless of age and duration of treatment.

Pancreatitis with an unfavourable outcome is generally observed in young children, or in patients with severe epilepsy, brain lesions or antiepileptic polytherapy.

Liver failure associated with pancreatitis increases the risk of a fatal outcome.

In the case of acute abdominal pain syndrome, as well as in the case of digestive manifestations such as nausea, vomiting and/or anorexia, it is necessary to consider the diagnosis of pancreatitis and, in the event of elevated pancreatic enzymes, to interrupt treatment and put in place the appropriate alternative therapeutic measures.

Suicidal ideation and behaviour

Suicidal ideation and behaviour have been reported in patients treated with antiepileptics for several indications. A meta-analysis of randomised, placebo-controlled trials of antiepileptics also showed a slight increase in the risk of suicidal ideation and behaviour. The causes of this risk are not known and the available data do not exclude the possibility of an increased risk for sodium valproate.

Consequently, patients must be closely monitored for any signs of suicidal ideation and behaviour and appropriate treatment should be considered.

Patients (and their carers) should be advised to seek medical advice should signs of suicidal ideation and behaviour occur.

Patients with known or suspected mitochondrial disease

Valproate may trigger or worsen clinical signs of the underlying mitochondrial disease caused by mutations of mitochondrial DNA as well as of the nuclear gene encoding POLG. In particular, cases of valproate-induced acute liver failure and associated deaths have been reported at a higher rate in patients with hereditary neurometabolic syndromes caused by mutations of the gene for the mitochondrial enzyme polymerase γ (POLG), e.g. Alpers-Huttenlocher syndrome.

POLG-related disorders should be suspected in patients with a family history or symptoms suggestive of a POLG-related disorder, including, among others, unexplained encephalopathy, refractory epilepsy (focal, myoclonic), status epilepticus at presentation, developmental delay, psychomotor regression, sensorimotor axonal neuropathy, myopathy, cerebellar ataxia, ophthalmoplegia, or migraine with occipital aura complications.

For a diagnostic evaluation of such disorders, POLG mutation testing should be performed, in accordance with current clinical practice (see section Contraindications).

Severe cutaneous adverse reactions and angioedema

Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme and angioedema have been reported in association with valproate treatment. Patients must be informed of the signs and symptoms of serious skin manifestations and must be closely monitored. If signs of severe cutaneous adverse reactions or angioedema are observed, rapid assessment is required and treatment must be discontinued if the diagnosis of severe cutaneous adverse reactions or angioedema is confirmed.

Drug interactions

The use of this medicine is not recommended in combination with lamotrigine and/or penems (carbapenems) (see section Interactions).

Cognitive or extrapyramidal disorders

Cognitive or extrapyramidal disorders may be associated with imaging of cerebral atrophy. Such a clinical picture may thus be confused with a dementia-type disease or Parkinson's disease. These disorders are reversible on discontinuation of treatment (see section Adverse effects).

Information related to the presence of sodium

This medicine contains 40 mg of sodium per tablet, which is equivalent to 2 % of the maximum recommended daily dietary intake of sodium of 2 g per adult set by the WHO. Take this into account in patients on a strict low-sodium diet.

Information on excipients with known effect

This medicine contains an azo colouring agent (E124) and may cause allergic reactions.

Precautions for use

Carry out biological monitoring of liver function before starting treatment (see section Contraindications) followed by periodic monitoring during the 6 first months, especially in patients at risk (see section Warnings and precautions "Severe hepatic impairment - Detection").

A moderate, isolated and transient increase in transaminases may be observed, particularly at the start of treatment, in the absence of any clinical sign.

In this case, it is advised to carry out a more complete biological assessment (in particular prothrombin level), to possibly reconsider the dose and to repeat the checks depending on the evolution of the parameters.

A haematological examination (complete blood count including platelets, bleeding time and coagulation panel) is recommended before treatment, then at 15 days and at the end of treatment, as well as before a surgical procedure and in case of haematomas or spontaneous bleeding (see section Adverse effects).

Urea cycle disorders and risk of hyperammonaemia

This medicine is contraindicated in patients with an enzymatic deficiency of the urea cycle. When an enzymatic deficiency of the urea cycle is suspected, metabolic investigations must be carried out before treatment due to the risk of hyperammonaemia with valproate. A few cases of hyperammonaemia associated with a stupor or coma have been described in these patients (see section Contraindications and Warnings and precautions "Patients at risk of hypocarnitinaemia" and "Severe hepatic impairment").

Patients at risk of hypocarnitinaemia

Administration of valproate may trigger the onset or worsening of hypocarnitinaemia, which may lead to hyperammonaemia (liable to cause hyperammonaemic encephalopathy). Other symptoms such as hepatic toxicity, hypoketotic hypoglycaemia, myopathy including cardiomyopathy, rhabdomyolysis and Fanconi syndrome have been observed, mainly in patients with risk factors for hypocarnitinaemia or pre-existing hypocarnitinaemia. Patients at increased risk of symptomatic hypocarnitinaemia when treated with valproate are patients with metabolic disorders, including carnitine-related mitochondrial disorders (see also section Warnings and precautions "Patients with known or suspected mitochondrial disease" and "Urea cycle disorders and risk of hyperammonaemia"), patients with impaired nutritional intake of carnitine, patients under 10 years of age, and patients concomitantly treated with pivalate-conjugated medicinal products or with other antiepileptic drugs.

Patients must be warned that they should immediately report any sign of hyperammonaemia, such as ataxia, altered consciousness or vomiting. Carnitine supplementation should be considered when symptoms of hypocarnitinaemia are observed.

Patients with primary systemic carnitine deficiency and corrected hypocarnitinaemia may only be treated with valproate if the benefits of valproate treatment outweigh the risks for these patients and in the absence of a therapeutic alternative. In these patients, carnitine monitoring should be put in place.

Patients with an underlying type II carnitine palmitoyltransferase (CPT) deficiency must be warned of the increased risk of rhabdomyolysis when taking valproate. Carnitine supplementation should be considered in these patients. See also the sections Interactions, Adverse effects and Overdose.           

            

Although this medicine is known to cause immunological manifestations only exceptionally, its use in a subject with disseminated lupus erythematosus should be weighed against the benefit/risk ratio.

At the start of treatment, patients must be informed of the risk of weight gain and of the appropriate measures, essentially dietary, that should be adopted to minimise it.

Valproate is excreted mainly in the urine, partly as ketone bodies; testing for ketonuria may give false positives in diabetic patients.

Alcohol intake is not recommended for the duration of treatment with DEPAKOTE.

Contraindicated combinations

+ St John's wort

Risk of decreased plasma concentrations and efficacy of the anticonvulsant.

Combinations not recommended

+ Lamotrigine

Increased risk of severe skin reactions (Lyell's syndrome).

Furthermore, increase in plasma concentrations of lamotrigine (decreased hepatic metabolism of lamotrigine by sodium valproate).

If the combination proves necessary, close clinical monitoring.

+ Penems (carbapenems)

Risk of convulsive seizures due to rapid decrease in plasma concentrations of valproic acid, which may become undetectable.

Administration of valproic acid in combination with carbapenems resulted in a decrease in plasma concentrations of valproic acid of the order of 60 to 100 % within approximately two days. Due to the rapid onset and magnitude of the decrease in plasma concentrations, concomitant administration of carbapenems in patients stabilised on valproic acid, where monitoring is not possible, should therefore be avoided (see section Warnings and precautions).

Associations requiring precautions for use

+ Acetazolamide

Increase in hyperammonaemia, with increased risk of encephalopathy.

Regular clinical and biological monitoring.

+ Aztreonam

Risk of convulsive seizures due to decrease in plasma concentrations of valproic acid.

Clinical monitoring, plasma assays and possible adjustment of the anticonvulsant dosage during treatment with the anti-infective and after its discontinuation.

+ Carbamazepine

Increase in plasma concentrations of the active metabolite of carbamazepine with signs of overdose. In addition, decrease in plasma concentrations of valproic acid due to increased hepatic metabolism of valproic acid by carbamazepine.

Clinical monitoring, plasma assays and dosage adjustment of both anticonvulsants.

+ Clozapine

Concomitant treatment with valproate and clozapine may increase the risk of neutropenia and clozapine-induced myocarditis. If concomitant use of valproate and clozapine is necessary, close monitoring of these two effects is required.

+ Felbamate

Increase in plasma concentrations of valproic acid, with risk of overdose.

Clinical monitoring, biological control and possible adjustment of the valproate dosage during treatment with felbamate and after its discontinuation.

+ Medicinal products containing oestrogens, including hormonal contraceptives containing oestrogens

Oestrogens are inducers of the UDP-Glucuronosyl Transferase (UGT) isoforms involved in the glucuro-conjugation of valproate and may increase its clearance; this could lead to a decrease in serum valproate concentration and potentially a decrease in its efficacy (see section Warnings and precautions). Consider monitoring serum valproate concentrations.

Conversely, due to the absence of enzyme-inducing effect, valproate does not reduce the efficacy of oestroprogestogens in women using hormonal contraception.

+ Metamizole

Metamizole may decrease serum valproate concentrations when co-administered, which may lead to a potential decrease in the clinical efficacy of valproate.

Monitor clinical response (seizure control or mood control) and consider monitoring serum valproate concentrations, where appropriate.

+ Methotrexate

Some cases describe a significant decrease in serum valproate levels after administration of methotrexate, with occurrence of convulsions.

Prescribers should monitor clinical response (seizure control or mood control) and consider appropriate monitoring of serum valproate levels.

+ Nimodipine (oral route and by extrapolation, injectable route)

Risk of increase in plasma concentrations of nimodipine by 50 %. Therefore, the nimodipine dosage should be reduced in case of hypotension.

+ Phenobarbital, and by extrapolation primidone

Increase in hyperammonaemia, with increased risk of encephalopathy.

Regular clinical and biological monitoring.

+ Phenytoin, and by extrapolation fosphenytoin

Increase in hyperammonaemia, with increased risk of encephalopathy.

Regular clinical and biological monitoring.

+ Propofol

Possible increase in blood concentrations of propofol. A reduction of the propofol dose should be considered in case of co-administration with valproate.

+ Rifampicin

Risk of occurrence of convulsive seizures, due to increased hepatic metabolism of valproate by rifampicin.

Clinical and biological monitoring and possible adjustment of the anticonvulsant dosage during treatment with rifampicin and after its discontinuation.

+ Rufinamide

Possible increase in rufinamide concentrations, particularly in children weighing less than 30 kg. In children weighing less than 30 kg: do not exceed the total dose of 600 mg/day after the titration period.

+ Topiramate

Increase in hyperammonaemia, with increased risk of encephalopathy.

Regular clinical and biological monitoring.

+ Zidovudine

Risk of increased adverse effects, particularly haematological, of zidovudine due to decreased metabolism by valproic acid.

Regular clinical and biological monitoring. A complete blood count to look for anaemia should be performed during the first two months of the combination.

+ Zonisamide

Increase in hyperammonaemia, with increased risk of encephalopathy.

Regular clinical and biological monitoring.

Other forms of interactions

+ Lithium

DEPAKOTE has no effect on lithemia.

+ Risk of hepatic damage

Concomitant use of salicylate derivatives should be avoided in children under 3 years due to the risk of hepatic toxicity (see section Warnings and precautions).

Simultaneous use of valproate and other anticonvulsants increases the risk of hepatic damage, particularly in young children (see section Warnings and precautions).

Use in combination with cannabidiol increases the incidence of increased transaminases. In clinical trials in patients of all ages receiving concomitant cannabidiol at doses of 10 to 25 mg/kg and valproate, an increase in ALT of more than 3 times the upper limit of normal was reported in 19 % of patients. Appropriate hepatic monitoring must be carried out when valproate is used in combination with other potentially hepatotoxic anticonvulsants, including cannabidiol. Dose reductions or discontinuation of treatment should be considered in case of significant abnormalities in hepatic parameters (see section Warnings and precautions).

+ Pivalate-conjugated medicinal products

Concomitant administration of valproate and pivalate-conjugated medicinal products (such as cefditoren pivoxil, adefovir dipivoxil, pivmecillinam and pivampicillin) should be avoided due to the increased risk of carnitine depletion (see section Warnings and precautions « Patients at risk of hypocarnitinaemia »). Patients for whom concomitant administration cannot be avoided must be placed under close monitoring in order to detect any sign or symptom of hypocarnitinaemia.

The "sodium divalproate" is composed of one molecule of sodium valproate and one molecule of valproic acid in a ratio of 1/1. The following clinical data are those obtained with sodium valproate.

Valproate is contraindicated (see sections Contraindications and Warnings and precautions) : during pregnancy; in women of childbearing potential, unless all conditions of the pregnancy prevention programme are met.

Use in adolescents and men of reproductive age: see section Warnings and precautions "Warnings" and the paragraph "Adolescents and men of childbearing potential" below.

Pregnancy and women of childbearing potential

Teratogenicity and neurodevelopmental effects following in utero exposure

In women, the use of valproate, whether in monotherapy or in polytherapy, is frequently associated with abnormal pregnancy outcomes. Available data show an increased risk of major congenital malformations and neurodevelopmental disorders, both in monotherapy and in polytherapy with valproate, compared with the population not exposed to valproate. Valproate has been shown to cross the placental barrier in animals and in humans (see section Pharmacokinetics).

In animals, teratogenic effects have been demonstrated in mice, rats and rabbits (see section Preclinical safety). In preclinical studies, a dose-dependent decrease in foetal weight has been demonstrated in animals exposed to valproate in utero compared with unexposed animals (see section Preclinical safety).

• Congenital malformations following in utero exposure

A meta-analysis (including registries and cohort studies) showed that approximately 11 % of children born to epileptic mothers treated with valproate in monotherapy during pregnancy had major congenital malformations. This is higher than the risk of major malformations encountered in the general population (approximately 2-3 %).

The risk of major congenital malformations in children exposed in utero to polytherapy with antiepileptics including valproate is higher than that associated with polytherapy with antiepileptics without valproate. This risk is dose-dependent during monotherapy with valproate, and the available data suggest that it is dose-dependent during polytherapy with valproate. However, no threshold dose excluding this risk could be determined.

Available data show an increased incidence of minor and major malformations. The malformations most often encountered include neural tube closure defects (on the order of 2 to 3 %), facial dysmorphism, cleft lip and cleft palate, craniosynostosis, cardiac, renal and urogenital malformations (notably hypospadias), limb malformations (notably bilateral radial aplasia) and polymalformation syndromes affecting various parts of the body.

Exposure in utero to valproate may also cause hearing impairment or deafness due to malformations of the ear and/or nose (side effect) and/or direct toxicity to auditory function. Cases describe unilateral and bilateral deafness or hearing impairment. Outcomes have not been reported for all cases. When outcomes are reported, there was no recovery in the majority of cases.

Exposure in utero to valproate may cause ocular malformations (notably coloboma and microphthalmia), which have been reported together with other congenital malformations. These ocular malformations may affect visual capacity.

• Neurodevelopmental disorders following in utero exposure

Studies show that valproate causes an increased risk of neurodevelopmental disorders in exposed children in utero. The risk of neurodevelopmental disorders (including autism) appears to be dose-dependent when valproate is used in monotherapy, but the available data do not allow determination of a dose excluding this risk.

When valproate is administered in polytherapy with other antiepileptic medicinal products during pregnancy, the risks of neurodevelopmental disorders in the child have also been significantly increased compared with those of the general population or those born to untreated epileptic mothers.

The period of risk for these effects is uncertain, and the possibility of a risk throughout pregnancy cannot be excluded.

When valproate is administered as monotherapy, studies conducted in preschool-aged children exposed in utero to valproate show that up to 30 to 40 % of them present developmental delays in early childhood, such as delays in speech and walking acquisition, reduced intellectual abilities, reduced verbal abilities (speech and comprehension) as well as memory disorders.

The intelligence quotient (IQ) measured in school-age children (6 years) exposed in utero to valproate is on average 7 to 10 points lower than that of children exposed to other antiepileptics. Although the role of confounding factors cannot be excluded, it is established that this decrease in IQ observed in exposed children in utero is independent of maternal IQ.

Data on the long-term course of these disorders are limited.

Available data from a population-based study show that children exposed in utero to valproate have an increased risk of presenting autism spectrum disorders (approximately 3 times more frequent) and childhood autism (approximately 5 times more frequent), compared with the unexposed population in the study.

Available data from another population-based study show that children exposed in utero to valproate have an increased risk of developing attention deficit/hyperactivity disorder (ADHD) (approximately 1,5 times more frequent), compared with the unexposed population in the study.

• Newborn small for gestational age (SGA) following in utero exposure:

Some epidemiological studies have suggested a higher risk of being born with a low weight for gestational age (SGA defined as a birth weight below the 10^e percentile adjusted for gestational age, stratified by sex) for children exposed to valproate in utero compared with unexposed children or children exposed to lamotrigine. SGA was observed in approximately 11-15 % of children exposed to valproate in utero, 8-9 % of children exposed to lamotrigine, and 5-10 % of children not exposed.

Data available in humans do not allow a conclusion on a potential dose-dependent effect.

• Other risks in the newborn

Very rare cases of haemorrhagic syndrome have been reported in newborns of mothers treated with valproate during pregnancy. This haemorrhagic syndrome is related to thrombocytopenia, hypofibrinogenaemia and/or a decrease in other coagulation factors. Afibrinogenaemia has also been reported and may be fatal. However, this syndrome must be distinguished from vitamin K-dependent coagulation factor deficiency induced by phenobarbital and enzyme inducers. A normal haemostasis panel in the mother does not rule out haemostatic abnormalities in the newborn. Therefore, at birth, a panel including a platelet count, a fibrinogen assay, coagulation tests and coagulation factors will be performed in newborns.

Cases of hypoglycaemia have been reported in newborns of mothers treated with valproate during the third trimester of pregnancy.

Cases of hypothyroidism have been reported in newborns of mothers treated with valproate during pregnancy.

A withdrawal syndrome (in particular agitation, irritability, hyperexcitability, nervousness, hyperkinesia, tone disorders, tremor, convulsions and feeding disorders) may occur in newborns of mothers treated with valproate during the third trimester of pregnancy.

Women of childbearing potential

In women of childbearing potential, treatment with DEPAKOTE must not be used except in cases of inefficacy or intolerance to other treatments. If no other alternative therapy (drug or non-drug) is possible, DEPAKOTE may only be initiated provided the pregnancy prevention programme is followed (see section Warnings and precautions), in particular:

• that they are not pregnant (plasma pregnancy test with a sensitivity of at least 25 mIU/mL negative at treatment initiation and at regular intervals during treatment);
• that they use at least one effective method of contraception;
• and that they are informed of the risks associated with valproate use during pregnancy.

In these women, the benefit-risk ratio must be carefully reassessed at regular intervals during treatment (at least annually). Treatment must absolutely be discontinued as soon as pregnancy is considered (or in case of discovery of a pregnancy).

Medicinal products containing estrogens:

Medicinal products containing estrogens, including hormonal contraceptives containing estrogens, may increase the clearance of valproate, which could lead to a decrease in serum valproate concentration and potentially a decrease in its efficacy (see sections Warnings and precautions and Interactions).

If pregnancy is planned:

In women planning a pregnancy, an experienced specialist physician in the management of bipolar disorders must be consulted, valproate treatment must be stopped and, if necessary, replaced by an alternative therapy (drug or non-drug) before conception and before contraception is discontinued.

Treatment with DEPAKOTE must not be interrupted without consulting an experienced specialist physician in the management of bipolar disorder.

Folic acid supplementation before pregnancy and in early pregnancy may reduce the risk of neural tube defects inherent to any pregnancy. For information, available data do not show a preventive effect of folic acid on malformations associated with valproate.

Pregnant women:

Valproate used in the treatment of bipolar disorder is contraindicated during pregnancy (see sections Contraindications and Warnings and precautions). Treatment with DEPAKOTE must absolutely be discontinued as soon as pregnancy is considered or in case of discovery of a pregnancy. Due to the risk of decompensation in the postpartum period, a reassessment by a specialist physician should be performed as early as possible after delivery.

In the case of a patient whose pregnancy has been exposed to valproate, she must immediately be referred to a physician specialised in the management of bipolar disorder in order to consider all alternative therapeutic options (drug or non-drug).

Patients whose pregnancy has been exposed to valproate, as well as their partners, must be referred to a specialist or physician experienced in teratology for assessment and to receive advice regarding the exposed pregnancy:

• specialised prenatal monitoring must be instituted in order to detect possible abnormalities affecting the neural tube or other malformations;
• close follow-up of the child's neurobehavioural development must be instituted and appropriate management must be put in place as early as necessary in case of need.

Adolescents and men of childbearing potential:

Potential risk of neurodevelopmental disorders in children whose father was treated with valproate in the 3 months before conception

A retrospective observational study conducted in 3 Nordic countries suggests an increased risk of neurodevelopmental disorders (NDDs) in children (aged 0 to 11 years) born to fathers treated with valproate in monotherapy in the 3 months preceding conception, compared with those whose fathers were treated with lamotrigine or levetiracetam in monotherapy, with an adjusted Hazard Ratio (HR) of 1,50 (95% CI: 1,09-2,07). The adjusted cumulative risk of NDDs ranged between 4,0% and 5,6% in the valproate group versus 2,3% to 3,2% in the combined lamotrigine/levetiracetam group.

Other population-based observational studies did not show an increased risk of NDD in children born to men treated with valproate in monotherapy during the 3 to 4 months before conception, compared with men treated with lamotrigine or levetiracetam in monotherapy.

Differences in study design, including control of confounding factors and population selection, may contribute to differences in study results. Furthermore, available data suggest that factors other than exposure to valproate, including the underlying paternal disease, could contribute to the observed association. Overall, the evidence regarding an increased risk of NDD in children of fathers treated with valproate during the 3 months preceding conception is conflicting, and the causal role of valproate is uncertain.

As a precautionary measure, the prescriber must inform adolescents and male patients of childbearing potential of this potential risk and discuss with them:

• the need to implement effective contraceptive measures during treatment with valproate and for at least three months after its discontinuation, including their partner (see section Warnings and precautions),
• not to donate sperm during valproate treatment and for at least three months after valproate discontinuation.

Valproate treatment in men and adolescents of childbearing potential must be regularly reassessed by the prescriber in order to determine whether valproate remains the most appropriate treatment. For male patients planning to conceive a child, therapeutic alternatives must be considered and discussed with the patients. Individual situations must be assessed in each case. It is recommended to seek advice from a physician specialised in the management of bipolar disorder if necessary.

A shared information acknowledgement form must be used, duly completed and signed at the time of treatment initiation by the specialist physician and at each annual reassessment of valproate treatment by any physician and the patient (or his legal representative).

Breast-feeding

Valproate is excreted in breast milk at a concentration between 1% and 10% of maternal serum levels. Haematological disorders have been observed in newborns/infants breastfed by women under treatment (see section Adverse effects).

The decision to discontinue breastfeeding or to suspend treatment with DEPAKOTE must take into account the benefit of breastfeeding for the child and the benefit of treatment for the woman.

Fertility

Cases of amenorrhoea, polycystic ovaries and increased testosterone levels have been reported in women treated with valproate (see section Adverse effects).

In men, administration of valproate may also impair fertility (particularly decreased sperm motility) (see section Adverse effects). In some cases, these fertility disorders are reversible after at least 3 months of treatment discontinuation. In a limited number of cases, a significant dose reduction has been reported to potentially improve fertility. However, in other cases, the reversibility of these male fertility disorders is not known.

Attention is drawn, particularly to drivers of vehicles and users of machinery, to the risk of drowsiness, especially in cases of anticonvulsant polytherapy or association with other medicinal products that may increase drowsiness.

Classification of expected frequencies:

Very common (≥ 10 %); Common (≥ 1 %-< 10 %); Uncommon (≥ 0,1 %-< 1 %); Rare (≥ 0,01 %-< 0,1 %); Very rare (< 0,01 %); Not determined (cannot be estimated from the available data)

Congenital, familial and genetic disorders

• Congenital malformations, neurodevelopmental disorders (see sections Warnings and precautions and Fertility, pregnancy and breastfeeding).

Blood and lymphatic system disorders

• Common: anemia, thrombocytopenia

Cases of dose-dependent thrombocytopenia, generally discovered systematically and without clinical consequences, have been described.

In cases of asymptomatic thrombocytopenia, if the platelet count and disease control allow, a simple dose reduction of this medicinal product most often leads to regression of this thrombocytopenia.

• Uncommon: leukopenia, pancytopenia.
• Rare: global bone marrow aplasia or pure red cell aplasia, agranulocytosis, macrocytic anaemia, macrocytosis.

Investigations

• Common: weight gain*
• Rare: decrease of at least one coagulation factor, abnormal coagulation tests (such as prolonged prothrombin time, prolonged activated partial thromboplastin time, prolonged thrombin time, increased INR) (see sections Warnings and precautions and Fertility, pregnancy and breastfeeding), vitamin B8 (biotin) deficiency/biotinidase deficiency
• Frequency not known: acquired Pelger-Huët anomaly**.

* As weight gain is a risk factor for the occurrence of polycystic ovary syndrome, the weight of patients must be closely monitored (see section Warnings and precautions).

** An acquired Pelger-Huët anomaly has been reported, with and without myelodysplastic syndrome.

Nervous system disorders

• Very common: tremor
• Common: extrapyramidal disorders**, stupor*, sedation, convulsion*, memory impairment, headache, nystagmus, nauseous or dizzy sensations
• Uncommon: coma*, encephalopathy*, lethargy*, reversible parkinsonian syndromes**, ataxia, paraesthesia
• Rare: diplopia, cognitive disorders of insidious and progressive onset (which may present as a complete picture of dementia syndrome), reversible a few weeks to a few months after stopping treatment**

* Cases of stupor or lethargy sometimes leading to transient coma (encephalopathy) under valproate have been observed, regressing on discontinuation of treatment or on dose reduction. These states most often occur during polytherapy (phenobarbital or topiramate in particular) or with a sudden increase in valproate doses.

** These symptoms may be associated with imaging showing cerebral atrophy.

Ear and labyrinth disorders

• Common: hearing loss

Respiratory, thoracic and mediastinal disorders

• Uncommon: pleural effusion (eosinophilic).

Gastrointestinal disorders

• Very common: nausea
• Common: vomiting, gingival disorders (mainly gingival hyperplasia), stomatitis, epigastric pain, diarrhoea, which may occur in some patients at the start of treatment but generally resolves within a few days without interruption of treatment.
• Uncommon: pancreatitis, the course of which may be fatal and which requires early discontinuation of treatment (see section Warnings and precautions).

Renal and urinary disorders

• Common: urinary incontinence.
• Uncommon: renal failure
• Rare: enuresis, tubulointerstitial nephritis, Fanconi syndrome.

Skin and subcutaneous tissue disorders

• Common: transient and/or dose-dependent hair loss, nail and nail bed disorders
• Uncommon: angioedema, skin reactions, hair disorders (such as abnormal hair texture, changes in hair colour, abnormal hair growth)
• Rare: Lyell's syndrome, Stevens-Johnson syndrome, erythema multiforme, DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome or drug hypersensitivity syndrome.
• Frequency not known: hyperpigmentation.

Endocrine disorders

• Uncommon: syndrome of inappropriate antidiuretic hormone secretion (SIADH), hyperandrogenism (hirsutism, virilism, acne, androgenic-type alopecia, and/or increased levels of androgen hormones)
• Rare: hypothyroidism (see section Fertility, pregnancy and breastfeeding)

Metabolism and nutrition disorders

• Common: hyponatraemia.
• Rare: hyperammonaemia* (see section Warnings and precautions), obesity.

* An isolated, moderate hyperammonaemia without changes in liver function tests may be observed, especially in cases of polytherapy, and should not lead to interruption of treatment. However, cases of hyperammonaemia with neurological symptoms (which may progress to coma) have also been reported, requiring further investigations (see sections Contraindications and Warnings and precautions : "Urea cycle disorders and risk of hyperammonemia" and "Patients at risk of hypocarnitinemia").

• Frequency not known: hypocarnitinemia (see sections Contraindications and Warnings and precautions).

Benign, malignant and unspecified tumors (incl. cysts and polyps)

• Rare: myelodysplastic syndrome

Vascular disorders

• Common: hemorrhage (see sections Warnings and precautions and Adverse effects)
• Uncommon: cutaneous vasculitis, mainly leukocytoclastic vasculitis.

General disorders and administration site conditions

• Uncommon: hypothermia, non-severe peripheral oedema

Hepatobiliary disorders

• Common: hepatopathies (see section Warnings and precautions).

Disorders of the reproductive system and breast

• Common: menstrual irregularities
• Uncommon: amenorrhea
• Rare: male fertility disorders (see section Fertility, pregnancy and breastfeeding), polycystic ovaries.

Musculoskeletal and systemic disorders

• Uncommon: decreased bone mineral density, osteopenia, osteoporosis and fractures in patients receiving long-term treatment with DEPAKOTE. The mechanism of action of DEPAKOTE on bone metabolism is not known.
• Rare: disseminated acute lupus erythematosus (see section Warnings and precautions), rhabdomyolysis (see section Warnings and precautions).

Psychiatric disorders

• Common: confusional state, hallucinations, aggressiveness*, agitation*, attention disorders*
• Rare: abnormal behaviour*, psychomotor hyperactivity*, learning difficulties*

* These effects are observed mainly in the pediatric population.

Paediatric population

Valproate is not recommended in the paediatric population for the treatment of manic episodes of bipolar disorder, see section Dosage and administration. The safety profile of valproate in the paediatric population is comparable to that in adults, but certain adverse effects are more severe or are mainly observed in the paediatric population. There is a particular risk of severe hepatic damage in infants and young children, in particular before the age of 3 years. Young children are also at particular risk of pancreatitis (see section Warnings and precautions). Psychiatric disorders such as aggressiveness, agitation, attention disorders, abnormal behaviors, psychomotor hyperactivity and learning disorders are mainly observed in the pediatric population.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/

The picture of acute massive poisoning usually includes a calm coma, more or less deep, with muscular hypotonia, hyporeflexia, miosis, decreased respiratory autonomy, metabolic acidosis, hypotension and cardiovascular collapse/shock.

A few cases of intracranial hypertension linked to cerebral oedema have been described.

Measures to be taken in a hospital setting are: gastric evacuation if indicated, maintenance of effective diuresis, cardiorespiratory monitoring. In very severe cases, extrarenal purification may be performed if necessary.

The prognosis of these poisonings is generally favourable; however, a few deaths have been reported.

The presence of sodium in formulations containing valproate may lead to hypernatraemia in cases of overdose.

Treatment

In case of valproate overdose resulting in hyperammonaemia, carnitine may be administered intravenously to attempt to normalise ammonium levels.

Pharmacotherapeutic class: ANTIEPILEPTIC, MOOD STABILISER, ATC code : N03AG01

Valproate exerts its pharmacological effects essentially at the level of the central nervous system.

These anticonvulsant properties are exerted against very varied types of convulsive seizures in animals and epilepsies in humans.

Experimental and clinical studies of valproate suggest two types of anticonvulsant action.

The first is a direct pharmacological effect related to valproate concentrations in plasma and brain.

The second is apparently indirect and probably related to metabolites of valproate persisting in the brain, or to modifications of neurotransmitters, or to direct membrane effects. The most generally accepted hypothesis is the gamma-aminobutyric acid (GABA) hypothesis, whose level increases after administration of valproate.

Valproate decreases the duration of the intermediate stages of sleep with a concomitant increase in slow-wave sleep.

As with its anticonvulsant activity, the main mechanism of action underlying the thymoregulatory activity of valproate appears to be linked to a strengthening of the GABAergic pathway.

The efficacy of sodium divalproate in the treatment of a manic episode has been established in 2 controlled trials, conducted in double-blind versus placebo in bipolar patients resistant or intolerant, or not, to lithium; the duration of treatment was 3 weeks, during which sodium divalproate was administered at the initial daily dose of 750 mg and was then gradually increased up to a maximum dose not to exceed 2 500 mg/day.

The molecule "sodium divalproate" is composed of one molecule of sodium valproate and one molecule of valproic acid in a ratio of 1/1.

Measurements of the total plasma level of valproic acid do not provide information on an increase in its free fraction in cases where protein binding is reduced, or in cases of overdose.

The various pharmacokinetic studies performed for valproate have shown that:

• The blood bioavailability of valproate after oral administration is close to 100 %.
• The volume of distribution is limited essentially to blood and rapidly exchanging extracellular fluids. Valproate diffuses into the CSF and into the brain.
• Passage across the placental barrier (see section Fertility, pregnancy and breastfeeding) :
  Valproate crosses the placental barrier in animals and in humans:
  • in animals, valproate crosses the placenta, in a manner similar to humans,
  • in humans, several publications have assessed the concentration of valproate in the umbilical cord of newborns at delivery. The serum concentration of valproate in the umbilical cord, representing the serum concentration of valproate in foetuses, was similar to or slightly higher than that of the mothers.
• The half-life is 15 to 17 hours.
• Therapeutic efficacy usually requires a minimum serum concentration of 40-50 mg/l, with a wide range between 40 and 100 mg/l. If higher plasma levels prove necessary, the expected benefits must be weighed against the risk of adverse effects, particularly dose-dependent ones. However, levels that remain above 150 mg/l require a dose reduction.
• The steady-state plasma concentration is reached in 3 to 4 days.
• Protein binding of valproate is very high. It is dose-dependent and saturable.
• The major pathway of valproate metabolism is glucuro-conjugation (approximately 40 %), mainly via UGT1A6, UGT1A9 and UGT2B7.
• Valproate is excreted essentially in the urine after metabolism by glucuro-conjugation and beta-oxidation.
• The valproate molecule is dialysable, but haemodialysis only affects the free fraction of blood valproate (approximately 10 %).
• Valproate is not an inducer of the enzymes involved in the metabolic system of cytochrome P 450, unlike most other antiepileptics. It therefore does not accelerate its own degradation, nor that of other substances such as oestroprogestins and vitamin K antagonists.

Animal studies show that exposure in utero to valproate results in morphological and functional alterations of the auditory system in rats and mice.

In vitro, valproate was not mutagenic in bacteria or in mouse lymphoma assays, and did not induce DNA repair in primary rat hepatocyte cultures. However, in vivo, contradictory results were obtained at teratogenic doses depending on the route of administration. After oral administration, the predominant route in humans, valproate induced neither chromosomal aberrations in rat bone marrow nor major lethal effects in mice. Intraperitoneal injection of valproate increased DNA strand breaks and chromosomal aberrations in rodents. In addition, an increase in sister chromatid exchanges in epileptic patients exposed to valproate has been reported in published studies compared with untreated healthy subjects. However, contradictory results were obtained when comparing data from epileptic patients treated with valproate with those from untreated epileptic patients. The clinical relevance of these DNA/chromosome findings is not known.

Non-clinical data from conventional carcinogenicity studies do not reveal any particular risk for humans.

Reproductive toxicity

Valproate induced teratogenic effects (malformations of several organ systems) in mice, rats and rabbits.

In mice, rats and rabbits, exposure in utero to valproate induced a dose-dependent decrease in fetal weight, intrauterine growth retardation and a reduction in crown-rump length compared with unexposed animals.

Behavioural abnormalities have been reported in first-generation offspring of mice and rats after exposure in utero. Certain behavioural changes were also observed in the second generation, and these were less pronounced in the third generation of mice after acute exposure in utero of the first generation to teratogenic doses of valproate. The underlying mechanisms and the clinical relevance of these findings are not known.

In repeated-dose toxicity studies, degeneration/atrophy of the testes, abnormal spermatogenesis and decreased testicular weight were reported in adult rats and dogs after oral administration of doses of 400 mg/kg/day and 150 mg/kg/day, respectively. The no observed adverse effect levels (NOAELs) associated with testicular effects are 270 mg/kg/day in adult rats and 90 mg/kg/day in adult dogs. Based on AUC (Area Under the Curve) extrapolations in rats and dogs, there may be no safety margin for humans.

In juvenile rats, decreased testicular weight was observed only at doses exceeding the maximum tolerated dose (from 240 mg/kg/day by intraperitoneal or intravenous route) and without associated histopathological changes. No effect on male reproductive organs was observed at tolerated doses (up to 90 mg/kg/day). In view of these data, juvenile animals were not considered more susceptible than adults to testicular disorders. The clinical relevance of these testicular findings for the paediatric population remains unknown.

In a fertility study in rats, administration of valproate at doses up to 350 mg/kg/day did not impair reproductive performance in males. However, male fertility disorders have been identified as an adverse effect in humans (see sections Fertility, pregnancy and breastfeeding and Adverse effects).

3 years.

No special precautions for storage.

No special requirements.

List II

Female children and adolescents, women of childbearing potential and pregnant womens: Initial annual prescription reserved for psychiatry specialists. Renewal not restricted.
Male adolescents and men of childbearing potential : Initial prescription reserved for psychiatry specialists. Renewal not restricted. 

Medication requiring particular monitoring during treatment: the prescription requires the annual signature by the physician and the female or male patient of the shared information attestation. Dispensing requires presentation of the co-signed annual attestation. 

 

Marketing authorisation (AMM)

CIP 3400935444271 (Plq/90).

Price:

23,40 euros (Plq/90).

Social security reimbursement at 65%. Collective.